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EFFECTS OF WEIGHT CHANGE ON METACHRONOUS ADENOMATOUS 
POLYPS 
ARZOO PATEL 
ABSTRACT 
Background 
Numerous epidemiologic studies have identified obesity as a vital risk factor for the 
development of colorectal cancer (CRC).  
 
Literature Review Findings 
More recently, obesity has been linked to the development of colorectal adenomatous 
polyps (adenomas), the precursor lesion of up to 80% of CRCs. The extent to which 
weight loss could reduce risk in obese patients is unclear.  
 
Proposed Project 
The proposed study is a randomized clinical trial that aims to evaluate the relationship 
between weight reduction and the prevalence of recurrent (metachronous) adenomas 
among obese patients in a safety-net health care setting. The intervention group will 
participate in a comprehensive, individually structured weight loss program in order to 
achieve successful long-term weight loss. The control group will receive no special 
recommendations about weight loss other than as part of “usual care”. Anthropometric 
measures (weight in kilograms [kg], height in meters squared [m2] and body mass index 
[BMI]) will be monitored annually until the time of surveillance colonoscopy which will 
		 vi 
occur in accordance with the U.S. Multi-Society Task Force recommendations. Statistical 
methods will be used to compare rates of recurrent adenomas among the two study 
groups after adjustments for duration of follow-up and potential confounders.  
 
Conclusion/Significance 
The results of this study will provide new evidence to support weight reduction as a 
preventive strategy for reducing CRC risk among obese patients.  
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INTRODUCTION 
Background 
Colorectal cancer (CRC) is the third most common cancer and the second leading cause 
of cancer death overall with an estimated 693,900 deaths occurring worldwide in 2012.1 
There were 1.4 million new cases reported in 2012 with the largest incidence in Australia 
and New Zealand, South America, North America and various parts of Europe. The 
majority of CRC cases are known to arise from pre-existing colorectal adenomas, which 
are commonly asymptomatic and are found on screening colonoscopy. Endoscopic 
removal of adenomas (polypectomy) has shown to greatly reduce CRC incidence and 
mortality.2 The identification of modifiable risk factors for CRC including cigarette 
smoking, alcohol use, red meat consumption, fiber intake, physical inactivity and obesity 
also provides a strategy for risk reduction through behavioral change.  
Obesity is a disease affecting more than 37.9% of American adults and is 
associated with the development of CRC, cardiovascular disease, breast cancer, type 2 
diabetes and many other illnesses.3 Several epidemiologic studies have shown a 
connection between obesity and adenoma formation. However, such an association 
between obesity and metachronous adenomas is unclear. Given the continued rise of 
obesity in many parts of the world, it remains an important goal to further evaluate its 
influence on disease processes such as metachronous adenomas.  
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Statement of the Problem 
Obesity is a known risk factor for colorectal adenomas4 and cancer.5,6 The underlying 
mechanism is not well understood but leading theories include chronic inflammation, 
immune activation and insulin resistance.7 Given that obesity is a modifiable factor and 
reduction in obesity could lead to reversal of adverse health outcomes, effective weight 
loss strategies need to be established. Although many individuals can successfully lose 
weight, most have difficulty maintaining the weight loss. There are various therapies that 
have been shown to improve weight maintenance including behavioral changes and 
comprehensive weight loss programs.8–10 However, despite the well-established 
association between obesity and adenoma risk, limited studies have evaluated the effects 
of weight reduction on metachronous adenomas in high-risk individuals.11,12 
Furthermore, the results of these studies have been heterogeneous. Consequently, further 
study is warranted in order to provide appropriate guidelines to the patients at risk for 
adenoma recurrence, especially in light of the obesity epidemic. 
 
Hypothesis 
Obese patients with sustained weight loss are less likely to have metachronous colorectal 
adenomas at surveillance colonoscopy than obese subjects without sustained weight loss. 
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Objectives and specific aims 
The prevalence of obesity in U.S. was 40% in women and 35% in men at the end of 
2014.13 Obesity is implicated as a cause of multiple health problems and, as previously 
noted, multiple studies have shown the correlation between obesity and development of 
colorectal adenomas and CRC. Lifestyle modifications to reduce obesity and achieve a 
healthy body weight are routinely recommended by practicing providers in patients with 
a history of colorectal adenomas, but there is inconsistent evidence on the effects of 
weight reduction and polyp recurrence rates. To address this issue, the specific aims of 
this study proposal are as follows.  
1. Determine the prevalence of colorectal adenomas in the obese patient population 
at Boston Medical Center undergoing their first screening colonoscopy.  
2. Implement and evaluate the effectiveness of weight reduction programs for obese 
patients with colorectal adenomas.  
3. Determine the prevalence of recurrent (metachronous) colorectal adenomas at 
surveillance colonoscopy among obese patients with and without sustained weight 
loss.  
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REVIEW OF THE LITERATURE 
Overview 
CRC is the third most common cancer and caused approximately 693,900 deaths 
worldwide in 2012.1 A recent study revealed 1.4 million new cases in the year 2012. The 
highest incidence of CRC is in Australia and New Zealand, various parts of Europe, 
North America and South America.14 Incidence is higher among males and African 
Americans. In the United States, incidence and mortality of CRC have been decreasing in 
adults >65 years but, there have been reported increases in younger adults <50 years 
old.15 In addition, incidence has been rising in developing countries such as Czech 
Republic and Slovakia, most likely attributed to the rising prevalence of obesity in these 
regions due to physical inactivity and consumption of high-calorie foods.14,16 In the 
United States, there was an estimated 26% decrease in mortality due to CRC between 
1975 to 2000. Microsimulation modeling has suggested that 14% of this decrease can be 
attributed to increased screening leading to early detection and prevention through 
removal of polyps, 9% due to reduction in exposure to risk factors that are known to 
contribute to CRC development and 3% to advancements in CRC treatment.17  
 CRC is caused by environmental and genetic factors, which are listed in Table 1. 
It is well recognized that the majority of CRC cases arise through the adenoma-to-
carcinoma pathway.2 It has been proposed that the transition of adenoma to cancer takes 
approximately 7 to 10 years. The likelihood of cancer progression increases  with the 
development of an advanced adenoma, which is defined as a tubular adenoma that is  
≥10mm in size, any adenoma or any size with high-grade dysplasia, villous features or 
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invasive cancer histologically.2 Apart from the inherited CRC syndromes, a positive 
family history of CRC confers the greatest relative risk (RR) of colon (RR = 1.94, 95% 
CI) and rectal cancer (RR = 1.27, 95% CI) development.18 Age is also an important risk 
factor among individuals without a family history2, with approximately 90% of all CRCs 
are diagnosed after the age of 50.  
Table 1. Risk factors for Colorectal Cancer19 
 
Alteration of modifiable risk factors, such as smoking cessation, increasing 
physical activity, weight reduction and decreased consumption of red and processed 
meats can potentially prevent CRC development. Additionally, some studies indicate that 
calcium, vitamin D and folate may have a role in CRC prevention.19 Chemoprevention 
via long-term use of aspirin (ASA), NSAIDs (sulindac) and COX-2 selective inhibitors 
(celecoxib), is another strategy that has been extensively studied for CRC prevention. 
Although all three of these medications have been shown to reduce CRC, they all have 
toxicities that make it difficult to advocate for the widespread use of these medications 
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for primary prevention of CRC.19 The U.S. Preventive Services Task Force (USPSTF) 
released guidelines in 2016 encouraging daily low dose (81 mg) ASA use in select 
patients between the ages of 50-59 years old in which the benefits of ASA outweighs the 
risks.20 The risk benefit analysis of NSAIDs and COX-2 inhibitor is still being studied 
further.  
Screening is the most widely used approach for decreasing both CRC mortality 
through early detection and incidence through the identification and removal of 
adenomas. There are various modalities that are available for screening, which can be 
broken down into two major categories: stool tests that detect primarily cancers and 
endoscopic/radiologic tests that detect both adenomas and cancer.21 The different types of 
stool tests and endoscopic/radiologic tests can be found in Figure 1. Numerous studies 
have been performed to evaluate screening strategies but there is no evidence that one 
screening modality has greater net benefit than another. Given this, USPSTF 
recommendations released in 2016 encourage screening in average-risk adults between 
the age of 50 to 75 years via any of the endorsed methods that is preferred by the patient, 
locally available, results in completion and adherence over time.22 For individuals who 
have a first-degree relative that was diagnosed at age <60 with CRC or an advanced 
adenoma, screening with colonoscopy is recommended every 5 years starting at age 40 or 
10 years younger than the age at which the youngest relative was diagnosed.23 
Improvements in screening alone over the past several years has led to a 14% decrease in 
mortality from CRC in the US, affirming the importance of this approach.17  
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Figure 1: Available screening tests for CRC 
While recent improvements in screening have led to decreased incidence and 
mortality in older adults (>65 years old), the rates are rising among young adults (<50 
years old). Early onset obesity has been implicated as a possible cause for this increase of 
young onset CRC.17 Multiple studies have revealed a correlation between obesity and the 
development of colorectal adenomas among men and women.4,24 Obesity is typically 
defined as a body mass index (BMI) ≥ 30 (Table 2). An individual’s BMI is determined 
by dividing the person’s weight in kilograms by their height in meters squared (BMI = 
kg/m2). BMI and its corresponding classification as defined by the World Health 
Organization (WHO) are listed in Table 2. Other measurements of obesity are waist 
circumference, visceral adipose tissue and waist-to-hip ratio; all of these parameters have 
been used in previous studies to evaluate the relationship of obesity and colorectal 
neoplasia development. Mechanism behind obesity causing colorectal carcinogenesis is 
not well established but several theories have risen involving insulin resistance and 
inflammation.  
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Table 2. Classification of BMI25 
  
Given excess weight is a known risk factor for CRC and colorectal adenoma 
development, many practicing physicians promote lifestyle modifications such as 
physical activity and diet changes to high-risk patients. In fact, increasing physical 
activity in order to reduce excess body weight has been shown to be an effective strategy 
in combating CRC26 with some studies proposing that a moderate increase in physical 
activity can be associated with an approximately 40-50% reduction in CRC.27,28  
Similarly, increased exercise to reduce weight has also shown to decrease colorectal 
adenomas.28,29 Though the association of weight change and colorectal adenoma has been 
proven, there are limited studies done to evaluate recurrent adenoma formation after 
weight reduction. Furthermore, no studies can be found that have specifically encouraged 
subjects with previous history of adenoma to participate in weight loss programs.   
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Existing research 
 
Pathophysiology 
Obesity is a worldwide epidemic that causes significant morbidity and mortality. The 
prevalence of obesity in U.S. was 40% in women and 35% in men at the end of 2014.13 In 
Massachusetts, the rate of obesity has increased from 15% in 2000 to 24.3% in 2016.30 
The prevalence of obesity in developing countries has also been noted to increase over 
the past several years due to the spread of Western lifestyle including physical inactivity 
and consumption of high-calorie foods.16 Obesity is a common risk factor for 
development of numerous diseases including but not limited to: colorectal cancer, breast 
cancer, hypertension, diabetes and coronary artery disease.  
 The pathophysiology behind obesity and colorectal neoplasia is not well 
established, although several mechanisms have been proposed (listed in Table 3).7 
Hyperinsulinemia is one of the prevailing mechanism. Studies have shown that the 
accumulation of body fat, particularly visceral fat, induces a state of insulin resistance, 
resulting in increased insulin secretion in order to maintain the body’s metabolic 
functions. Increased insulin levels in the body bind with insulin-like growth factor 
receptors (IGFR) in the colonic epithelium. This leads to activation of the Ras-mitogen-
activated protein kinase (Ras-MAPK) pathway and increased concentrations of IGF-1, 
both of which ultimately result in proliferation of colon epithelial cells (colonocytes) and 
transformed CRC cells. IGF-I also promotes tumorigenesis through the Ras-MAPK 
pathway.7 An additional explanation for colorectal neoplasia in the obese population is 
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the presence of inflammation. Obese subjects have increased release of several 
inflammatory mediators such as interleukin (IL)-17, IL-6, IL-22 and tumor necrosis 
factor (TNF)-a, which cause chronic low-grade inflammation and promote 
carcinogenesis. Recently, it has been postulated that dysbiosis in the gut microbiota of 
obese subjects may also play a role in colorectal neoplasia formation.7,31 
Table 3. Potential mechanisms of obesity induced colorectal carcinogenesis7 
 
 The recommended treatment for obesity encompasses a comprehensive lifestyle 
intervention consisting of diet, exercise and behavioral modification. A description of 
these interventions can be found in Table 4. The longest clinical trial available on 
lifestyle interventions for weight management is the Look AHEAD study which was 
started in 2001 and had a follow-up period of 11.5 years. The primary goal of this multi-
center trial was to determine if an intensive lifestyle intervention designed to decrease 
weight and increase physical activity, would decrease cardiovascular morbidity and 
mortality in overweight/obese patients with type 2 diabetes.32 Approximately 5000 
overweight and obese individuals (BMI ³ 30 kg/m2 ) were randomized to one of 2 
groups: (1) an intervention group that received an intensive lifestyle intervention (ILI) 
consisting of diet changes and increased physical activity, with an end goal of weight 
reduction; or (2) a control group received diabetes support and education (DSE). Both 
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programs were administered over a 4-year period after which participants were followed 
for up to 11.5 years.32  
 The study showed that the ILI subjects lost an average of 4.7% of their initial 
weight during the first 4 years compared to 1.1% weight reduction for DSE subjects (p 
<0.0001). From the 887 subjects in the ILI category who lost ³10% of their initial body 
weight during the first year, 374 (42.2%) sustained this loss at year four of the study. The 
results of this study provide strong evidence that a comprehensive lifestyle intervention 
can induce weight loss and maintain weight loss in approximately 45% of patients at four 
years.33  
Table 4. Description of diet, physical activity and behavior therapy34 
 
Overall, there is an extensive body of research on interventions that lead to 
healthy body weight; including dietary consultations, internet-based self-help programs, 
primary care consultations and commercial weight loss programs.10 All of these 
interventions are moderately effective in delivering weight loss. However, research has 
shown that individually structured comprehensive weight loss programs result in the 
greatest long-term weight loss.8–10 
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Obesity and colorectal adenoma 
Numerous studies have taken place to elucidate the role of obesity in the development of 
colorectal adenoma, yet the results of such studies have been heterogeneous. The 
majority of such studies have evaluated this relationship using BMI, waist-to-hip ratio or 
most recently using visceral adiposity.35 Most36–39, but not all,40  have shown an 
association between excess body weight (obesity) and adenoma formation. Kitahara et 
al39 performed a prospective analysis of BMI and its effects on colorectal adenoma.. They 
observed that a BMI ³ 30 kg/m2 in males, but not females, was linked with an increased 
risk of developing incident distal colorectal adenoma (OR 1.32; 95% CI, 1.06-1.65; p for 
trend = 0.01) and CRC (HR 1.48; 95% CI, 1.16-1.89; p for trend = 0.002) when 
compared to their normal weight counterparts. Other studies have also noted an increased 
prevalence of adenomas in the male population29,36,38 regardless of their BMI 
classification and some have seen a similar trend in African Americans36 as well. It 
remains unclear why the difference in prevalence exists between genders; however, it is 
theorized that sex hormones in females such as estrogens and progestin, may be 
protective factors.41 
Ben et al42 published a meta-analysis in 2012 that demonstrated that a 5-unit 
increase in BMI attributed to a 19% increased risk in the development of colorectal 
adenoma. No substantial differences were noted between gender and the type of adenoma 
in this study. The study did find that the risk of developing a colon adenoma was higher 
than a rectal adenoma in the setting of increasing BMI.  
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Weight change and colorectal adenomas 
Evaluation of the connection between obesity and colorectal adenoma has taken place by 
observing populations that have attempted to reduce their BMI. Sedjo et al 37 performed a 
10-year prospective study that included participants from a multi-center Insulin 
Resistance Atherosclerosis Study. The results showed that excess body weight was 
correlated with increased risk of adenoma at time of colonoscopy, especially among 
females. It was also determined that individuals who had a >4-pound weight gain over a 
5-year period had an increased risk of colorectal adenoma compared to those who 
maintained weight. Overall, a 1.5- to 3.4-fold increase in adenoma was noted among 
obese subjects.37 
 
Physical activity and colorectal adenomas 
In 2012, the effects of exercise on colorectal adenoma were investigated by Sanchez et 
al28 in a colorectal cancer screening population of 1,862 subjects. Physical activity in this 
group of patients was assessed by a questionnaire that inquired about the level of exercise 
the subjects partake in weekly and yearly. The outcomes showed a statistically significant 
decrease in incidence of any polyps (p > 0.01) and in adenomas (p = 0.03) in subjects 
who exercised at least one hour per week compared to participants who did not exercise 
regularly. A decreased rate of advanced adenomas was also noted in those who exercised, 
but this difference was not statistically significant (p = 0.06). The study also found that 
African American subjects and Hispanics benefited the most from exercise. Further 
review of the results established that subjects who were obese and exercised, were 
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significantly less likely to develop any adenomas (p=0.023) and advanced adenomas (p= 
0.011) compared to those who were obese and didn’t exercise.28  
The results of a similar study were published in 2005 examining the effects of 
physical activity and BMI on polyps.  The conclusion of this study was that males who 
had high total daily energy expenditure had a lower risk of developing advanced 
neoplastic polyps than those with the lowest energy expenditure; no such association was 
noted for females.29 Based on the results from these numerous studies, it can be 
concluded that reduction in obesity by weight loss and increased physical activity, can 
result in decreased development of adenomas. 
 
Obesity and adenoma recurrence 
Several predictors of recurrent (metachronous) adenomas have been established by 
previous studies, which can be broken down into two categories: patient characteristics 
and polyp characteristics. Baseline colonoscopy polyp characteristics that predict risk of 
adenoma recurrence include increased size of lesion, multiplicity and advanced histology 
of the lesion.2 Patient characteristics that can lead to recurrence of adenomas include 
older age and male sex. Inconsistent and limited data exist regarding other potential 
patient risk factors, such as excess body weight.  
One of the first reports assessing the relationship between body size and 
metachronous adenomas was published in 2007 by Jacobs et al.43 The primary aim of this 
study was to evaluate the effects of waist circumference and/or obesity on metachronous 
adenomas. The secondary objective was to evaluate if the effects of body size and 
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recurrence were different based on gender or family history of CRC. The study 
population was pooled from two randomized clinical trials. The first trial evaluated the 
effect of high-fiber versus low-fiber supplementation on risk of adenoma recurrence, 
while the second trial evaluated the effects of ursodeoxycholic acid versus placebo on 
adenoma recurrence. Researchers measured height and weight of subjects to ascertain 
BMI, while waist and waist and hip measurements were reported by the participants. 
Based on these measures, the subjects were categorized according to BMI (Table 2). 
Forty-five percent of the participants were found to be overweight and 24% were 
obese. Significantly more adenomas were detected in the baseline colonoscopy in 
subjects that were overweight (p<0.01) or obese (p<0.05) compared to normal weight 
controls. At follow-up, overweight (BMI 25-29.99) participants showed increased rates 
of advanced but not non-advanced adenomas, while obese (BMI ³ 30 kg/m2) participants 
exhibited increased rates of non-advanced adenomas compared to normal weight 
participants. After adjustment for potential confounders, obese participants had a non-
significant 17% increase in the odds of recurrence (OR=1.17; 95% CI=0.92-1.48) that 
was completely attenuated by inclusion of waist size in the model.  
When stratified by gender, the data showed that there was no association between 
BMI and risk of recurrence in women, compared to the statistically significant increased 
risk of recurrence found in men (OR=1.36; 95% CI = 1.01-1.83; p for trend = 0.04). No 
association was found for waist circumference and adenoma recurrence in either gender. 
A positive correlation between BMI and metachronous adenoma was also noted among 
study participants with a family history of CRC; those who had family history of CRC 
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and were obese were twice as likely as control subjects to have adenoma recurrence (p 
for trend = 0.006). A limitation of this study is that the subjects were followed for only 
three years. Nonetheless, the results of the study established a significant association 
between body size and short-term adenoma recurrence rate, especially in the male 
population.  
In a different study, Jacobs et al.44 further assessed the relationship between BMI 
and recurrent colorectal neoplasia. In this study, anthropometric measurements were 
obtained for a pool of 8,213 participants who had underwent baseline colonoscopies in 7 
prospective studies on colorectal adenomas. Analysis of the overall study population 
yielded a statistically significant trend of increased metachronous neoplasia (p for trend 
<0.001) and non-advanced adenoma with rising BMI (p for trend <0.001). Trend was not 
statistically significant for increasing BMI and advanced neoplasia (p for trend <0.07). It 
was furthermore noted that the relationship between BMI and recurrent neoplasia was 
confined to proximal lesions rather than distal lesions. A limitation of this study is 
potential for measurement error due self-reported anthropometric measurements provided 
by a few of the pooled studies. In summary, this study provided statistically significant 
information on BMI and its link to metachronous neoplasia and metachronous non-
advanced adenoma. 
Kitahara et al39 also examined the association between BMI and recurrent 
adenomas among subjects participating in the Prostate, Lung, Colorectal and Ovarian 
Cancer Screening Trial. Obese men with a BMI ³ 30 kg/m2 had a borderline increased 
risk of developing metachronous adenomas compared to normal weight males (OR 1.50; 
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95% CI, 0.98 to 2.30; p for trend = 0.07). Again, no association between BMI and 
recurrence was detected among the female participants.   
In the aggregate, the results of these studies provide compelling evidence that 
there is an association between BMI and metachronous adenoma, especially in men. 
 
Weight change and adenoma recurrence 
In 2012, Laiyemo et al11 published the first prospective study on the effects of weight loss 
and adenoma recurrence. This was a four-year study that included 1,826 patients who 
were participating in the Polyp Prevention Trial (PPT). All participants underwent 
baseline colonoscopies and had weight and height measurements taken by study 
personnel. Approximately 47.5% of subjects were classified as overweight and 26.9% as 
obese. Results demonstrate that patients with a baseline BMI ³ 30 kg/m2 had a significant 
19% increased risk of metachronous adenoma and 62% increased risk of metachronous 
advanced adenoma. Review of the weight change results from initial colonoscopy to 
follow-up colonoscopy (four years later), revealed that weight loss or weight gain was not 
associated with recurrence of advanced or non-advanced adenoma. Overall, the 
conclusion of the study was that obesity was linked to increased risk of metachronous 
adenoma but weight loss or gain had no effects on recurrence, regardless of baseline 
BMI.11 
 Contrary to these findings, Jung et al12 concluded that weight gain was associated 
with risk of adenoma recurrence. This study observed the association between weight 
change and adenoma recurrence over a 2.2-year time period and included total of 5,297 
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participants; 2,176 with baseline adenoma and 3,121 without adenoma. Subjects 
underwent an initial colonoscopy between 2010 and 2011 and had a repeat colonoscopy 
between 2012 and 2013. Weight change for the participants was categorized into four 
quartiles and reported as the difference in weight from initial colonoscopy and follow-up 
colonoscopy. 
Examination of the results revealed that compared to the subjects in Q1 (weight 
loss <-1.6kg), the subjects in Q4 (weight gain of ³ 1.9 kg) had a greater risk of any 
adenoma recurrence (adjusted HR 1.29; 95% CI). No association was noted between 
advanced adenoma recurrence and weight change (p for trend = 0.852). When stratified 
by gender, males appeared to have higher risk of any adenoma occurrence (p for trend = 
0.020). Analysis of baseline BMI and risk of adenoma recurrence revealed that subjects 
who had higher baseline BMI had an increased risk of advanced adenoma recurrence (p 
for trend = 0.029). Observation of the participants who had no evidence of baseline 
adenoma revealed that increasing quartiles of weight change was not associated with 
development of adenomas. However, it was noted that high baseline BMI was associated 
with an increased risk of developing any adenoma (p for trend <0.001).12 
In summary, the results of this study revealed that increasing weight was 
associated with increased risk of any adenoma recurrence but overall weight change, had 
no effects on advanced adenoma recurrence. When analyzing by BMI, it was found that 
there was increased risk of recurrence of advanced adenoma and any adenoma formation 
in the subjects with high baseline BMI. The limitations of this study include lack of 
generalizability and short study period. The study population was Korean, mostly male 
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(86%) and <50 years of age. Hence, it is difficult to generalize these findings to other 
races, gender and higher age groups. Another limitation is that the study took place over a 
short timespan consisting of 2.2 years which makes it difficult to evaluate the long-term 
effects of weight change. Additionally, the study did not analyze potential confounders 
such as diet and physical activity.  
Similar to the previous study, Yamaji et al45 established an association between 
weight change and adenoma recurrence. The retrospective study included 2,568 subjects 
who had received an initial colonoscopy and underwent a second colonoscopy one year 
later. The goal of the study was to determine incidence of recurrence based on initial BMI 
and based on weight changes during one year. Approximately 27% of the participants 
were overweight and 3% were obese. Review of the results revealed that the incidence of 
both baseline and recurrent adenomas increased with increasing baseline BMI. Moreover, 
the incidence of recurrent adenoma was significantly lower in those subjects who lost 
>5% of their body weight during the 1-year follow-up period compared to those who had 
no weight reduction (p = 0.01). A limitation of this study is again the lack of 
generalizability to other ethnicities and BMI categories, since the subjects in the study 
were Japanese and only 3% were obese. Another limitation is that the study took place 
over a short period of time, which increases the chance that the adenoma that was found 
on the second colonoscopy might have been an adenoma that was missed on the initial 
colonoscopy.45  
The reason behind the disparity in various studies between weight change and 
adenoma recurrence are unclear and the results of these studies have been heterogeneous. 
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However, it is reported by most studies that baseline BMI is an accurate predictor of 
adenoma recurrence. Given this, it is an important goal to further evaluate the 
relationship between obesity and recurrent adenoma by exploring the effects of weight 
reduction on adenoma recurrence rates. Furthermore, no studies can be found that have 
encouraged healthy body weight via utilization of structured comprehensive weight loss 
programs in the patient population with colorectal adenoma. Therefore, the proposal of 
this study is to evaluate the relationship between weight change and adenoma recurrence 
in a patient population that is specifically encouraged to participate in an individually 
structured comprehensive weight loss program.  
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METHODS 
Study Design 
We will conduct a prospective, two-arm randomized controlled trial to evaluate the 
impact of an intensive weight reduction program on the prevalence of metachronous 
adenomas among obese individuals.   
 
Study setting 
The study will be conducted at Boston Medical Center (BMC), a nonprofit academic 
medical center that is affiliated with Boston University School of Public Health and 
School of Medicine.  It is a large safety net hospital in New England and serves mostly to 
the minority patient population with approximately 72% of patients being from the under-
served populations.   
 
Study Population 
The study sample will be comprised of obese (BMI ³30), English- or Spanish-speaking 
average-risk individuals 50-70 years of age with newly diagnosed colorectal adenoma.  
Patients meeting eligibility criteria (Table 5) must also be under the care of a primary 
care physician at BMC with a prearranged office visit within 3 months of the baseline 
colonoscopy.  Patients at an increased risk of colorectal neoplasia due to a personal 
history of colorectal cancer or adenomas, family history of colorectal cancer or advanced 
colorectal adenoma affecting one or more first degree relatives under the age of 60, or 
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chronic inflammatory bowel disease will be excluded. Inclusion and exclusion criteria for 
the study can be found in Table 5.  		
Table 5. Inclusion and exclusion criteria for the study 
 
Sample Size and Power Estimates 
Assuming 45% prevalence of recurrent adenomas in the control group11, a total sample of 
400 subjects (200 per each study arm) would provide greater than 0.8 power for detecting 
a 15% difference at the p<0.05 level. BMC currently performs more than 300 screening 
colonoscopies per year, of which 38% are done on patients with BMIs’ >30.47 
 
Recruitment 
Potential study participants with adenomas will be identified though weekly audits of 
BMC’s electronic endoscopy database (Provation) and electronic health record (EHR).   
Individuals meeting inclusion criteria will be contacted directly by telephone within 2 
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weeks of their colonoscopy to provide an overview of the proposed study, to verify 
eligibility and to explore their interest in participating in the proposed study. Eligible 
patients who agree to participate will be formally enrolled in the trial just prior to the 
prearranged office visit with their primary care providers. Participants will receive a $25 
incentive to compensate them for participation.  
 
Study Activities 
Eligible patients who agree to participate via telephone will be instructed to meet with 
study personnel one hour prior to the prearranged appointment with their primary care 
physician.  After obtaining informed consent, patients will be asked to complete a short, 
self-administered baseline risk assessment questionnaire that inquires about demographic 
information and exposure to putative risk factors for CRC and colorectal adenomas. After 
completing the survey, patients will be randomized 1:1 using a computer-generated 
randomization system to either an intervention arm (intensive weight reduction program) 
or control arm (usual care).  Patients in the intervention arm will be given a written 
reminder to hand to their provider requesting that they generate a referral for the patient 
to the weight reduction program at BMC (described below).  The control group will 
receive no special recommendations about weight loss other than as part of “usual care”.  
Patients in both arms of the study will have annual visits with their primary care provider 
and/or dietician (intervention patients only) to obtain anthropometric measures up to the 
time of their surveillance colonoscopy. Surveillance colonoscopies will be performed in 
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accordance with the 2012 U.S. Multi-Society Task Force (USMSTF) guidelines (Table 
6).46 
Table 6. USMSTF 2012 Recommendations for Surveillance Colonoscopy46 
 
 
Pre-study seminars 
Prior to patient recruitment, pretrial seminars will be conducted with General Internal 
Medicine and Family Medicine primary care providers at BMC.  The intent of the 
seminars will be to provide an outline of the proposed study and to elicit support in 
referring intervention patients to the weight reduction program. 
 
Intervention 
The weight management program at BMC utilizes dietitians to provide individually 
structured guidance on weight reduction including behavioral change strategies, exercise 
promotion and healthy food choices. The subjects will be advised to follow-up with their 
dietitian at least once every 2-3 months for the first year. Each subject will receive a 
reminder call 1 week prior to the visit to optimize adherence. Following the first year, the 
subject and their dietitian can schedule visits as needed with at least one annual visit with 
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the dietitian. Anthropometric measures (weight, height, BMI) will be recorded in EHR at 
each dietitian visit.  
 
Data Collection 
Eligible patients who agree to participate in the proposed study will complete a brief 
survey that captures demographic information and baseline risk factors. Characteristics of 
all colorectal adenomas detected at screening and surveillance colonoscopy and will be 
recorded, including size, number and histologic features (tubular, villous, tubulovillous, 
low- or high-grade dysplasia).  Advanced adenomas will be defined as an any sized 
adenoma with villous features or high-grade dysplasia or a tubular adenoma ≥ 10 mm in 
size. All subjects participating in the study will have weight (kilograms [kg]) and height 
(meters squared [m2]) measurements on the day of their screening colonoscopy, in 
accordance with standard procedure, and then at least annually at the time of follow-up 
visits with their primary care provider and/or dietician until the time of the surveillance 
colonoscopy.  BMI will also be calculated at each visit by dividing the person’s weight 
by their height (BMI = kg/m2). BMI and its corresponding classification as defined by the 
World Health Organization (WHO) are listed in Table 2. Percent weight change will be 
calculated at the end of the study by subtracting the weight on screening colonoscopy day 
from the weight on surveillance colonoscopy day. All data will be stored on an Excel 
spreadsheet of a research-only designated computer.  
	26 
Main Outcome Measures 
The primary outcome of this study will be the prevalence of recurrent polyps at the time 
of the surveillance colonoscopy.  Findings will be accessed through EHR review 
conducted independently by 2 study investigators.  Patients with incomplete 
colonoscopies due to poor bowel preparation will be excluded from the analysis unless 
they undergo a complete colonoscopy within 3 months. Patients will be excluded from 
analysis if the cecum cannot be reached during the colonoscopy for reasons other than 
obstructing neoplasm or poor bowel preparation, unless they undergo a complete 
colonoscopy within 3 months.  Additionally, participants will be excluded if they had 
unretrieved polyp specimens.  Secondary outcomes will include the prevalence of 
adenomas at baseline, the prevalence of recurrent adenomas after stratification by sex, 
prevalence of recurrent advanced adenomas, participation in the weight reduction 
program, and weight change at the time of the surveillance colonoscopy. 
 
Data Analysis 
All statistical calculations will be performed using a statistical software system by a 
statistician consultant. Descriptive statistics will be used to describe baseline 
characteristics, prevalence rates and anthropometric data.  As a check on randomization, 
demographic characteristics between the two study arms will be compared using 
student’s t-tests for continuous variables and the chi-square test of independence for 
categorical variables. The risks of metachronous adenoma and development of any 
adenoma and advanced adenomas due to weight or BMI change will be analyzed using 
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the Pearson’s correlation coefficient.  Adjustments will be made for duration of follow 
(person-years as defined by the sum of the follow-up from the enrollment until the time 
of the surveillance endoscopy) and for potential confounders (age, sex and covariates 
identified in the baseline survey of risk factors).  
 
Timeline and Resources 
Table 7. Timeline for the proposed trial 
Timeline 
Fall 2017 • IRB submission and approval 
January 2018-2019 
• Begin recruitment 
• Initial assessment by study investigator (obtain 
anthropometric data, administer questionnaire) 
• Weight management program referral 
January 2018- 
December 2023 
• Participation in weight management program 
• Annual follow-up appointments with primary care 
provider and/or dietitian 
January 2021- 
December 2023 • Surveillance colonoscopy (3-year or 5-year) 
Spring 2024 • Data analysis 
• Preparation and submission of manuscript 	
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Table 8. Necessary resources for the proposed trial 
Resources 
Clinical 
• Access to BMC’s EHR 
• Weight management program consultations with a 
dietitian 
• Primary care provider visits 
Supplies 
• Computer 
• Statistical software 
• Consent forms 
• Clinic facility use 
• Telephone 
Administrative 
• Statistical consulting 
• Clinical research personnel for purposes of 
consenting, setting up follow-up appointments, data 
collection and data entry 
Other • Incentive compensation for study participants 
 
Institutional Review Board 
An application for full-board review will be submitted to the Institutional Review Board 
(IRB) of Boston University Medical Center. Approval from the IRB will be obtained 
before subject recruitment is started. 
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CONCLUSION 
Discussion 
This study is unique in that it will be the first randomized clinical trial examining the 
impact of weight reduction on recurrent adenomas in obese patients.  Besides its 
uniqueness, the study has several notable strengths.  These include the use of dietitians to 
implement a comprehensive, individually structured weight reduction plan which has 
previously been shown to achieve sustained weight loss and the inclusion of a diverse 
patient population, which enhances generalizability of the findings.  Moreover, this study 
will help establish the relationship between weight loss and metachronous adenomas, 
which will support in making appropriate recommendations for patients at high risk for 
adenoma recurrence.  
Despite the aforementioned strengths, there are also several notable limitations.  
First, the study targets individuals who are classified as obese with a BMI ³ 30 kg/m2, 
which limits its generalizability to overweight individuals with a BMI between 25-29.99 
kg/m2.  Second, there may be variation in adenoma detection rates among the 
endoscopists at BMC.  Third, patients in the intervention arm will participate in an 
individually structured weight loss program consisting of diet, exercise and behavioral 
modification, thus precluding an in-depth analysis of patient adherence and identification 
of the program’s most effective component(s).  Lastly, the surveillance colonoscopy 
timeframe will vary because of baseline findings, which might impact on the overall 
effectiveness of the intervention given the latency for polyp development.  
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Additionally, there are several anticipated obstacles that could negatively impact 
on the study’s outcomes, the foremost of which is, adherence to the weight reduction 
plan.  This obstacle will be addressed by scheduling regular follow-up visits with the 
patient’s dietitian and monthly reminder calls from research staff.  Secondly, the 
proposed enrollment period may be insufficient to recruit the target sample and so we are 
prepared to extend the enrollment period by 6 to 12 months if necessary.  Thirdly, 
patients might be lost to follow-up for their surveillance endoscopy and/or primary care 
clinic appointments due to the study’s duration.  This issue will be addressed by reminder 
phone calls the week prior to both the primary care and endoscopy appointments.  
 
Summary 
Several studies have displayed a positive association between increasing BMI and 
recurrent adenomas, but scarce and conflicting literature is present on the effects of 
weight reduction on metachronous adenoma risk.  Furthermore, there are no studies 
reporting the benefits of specific weight loss programs in the obese population with 
colorectal adenomas.  However, there is extensive research on interventions that lead to 
healthy body weight, including dietary consultations, Internet-based self-help programs, 
primary care consultations and structured commercial weight loss programs.10 In the 
aggregate, these studies have shown that lifestyle modification via individually structured 
comprehensive weight loss programs have a greater long-term effect on weight loss than 
less intensive, generic interventions.8–10 Therefore, this study proposes an innovative 
randomized clinical trial implementing the use of individually structured weight loss 
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programs to further evaluate the relationship between weight reduction and risk of 
metachronous adenomas in obese patients.  
 
Public health significance 
Obesity is a disease affecting more than 37.9% of American adults. In addition to being 
linked to the development of CRC, it also causes other disease processes such as 
cardiovascular disease and type 2 diabetes. By establishing the role of obesity on the 
formation of recurrent adenomas, this study could potentially lead to the release of 
modified surveillance guidelines for high-risk individuals such as the obese patient 
population. Furthermore, this study will allow for the highest risk group, the obese 
population, to engage in a weight reduction program which could lead to an overall 
healthier future for the patient and could lead to a significant decrease in morbidity and 
mortality from obesity.  
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